C5
C5G.F Orexo AB (publ)
- Market cap
- EUR 4.57M
- P/E
- -
- P/B
- 0.17x
- ROE
- -248.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is C5G.F undervalued?
Graham numberThe Graham number of Orexo AB (publ) cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Orexo AB (publ) fundamental analysis
No fundamental analysis for Orexo AB (publ) yet.
Orexo AB (publ) stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Orexo AB (publ)
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is deve…
Full company profileOrexo AB (publ) financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Orexo AB (publ) annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 706M | 644M | 783M | 845M | 664M | 565M | 624M | 639M | 29.7M | 26.0M | 12.4M |
| Gross Profit | 556M | 479M | 611M | 739M | 598M | 486M | 522M | 550M | 11.0M | 11.5M | 11.6M |
| Operating Income | 51.7M | 19.4M | 77.3M | 221M | -37.7M | -225M | -214M | -108M | -433M | -341M | -367M |
| EBITDA | - | 72.4M | 130M | 288M | 16.8M | -141M | -73.9M | -22.0M | -252M | -286M | -332M |
| Net Income | 29.0M | 23.2M | 138M | 219M | -84.4M | -224M | -178M | -128M | -203M | 639M | -441M |
| EPS | - | 0.67 | 3.99 | 6.31 | -2.46 | -6.52 | -5.17 | -3.72 | -5.88 | 18 | -13 |
| Balance Sheet | |||||||||||
| Total Assets | 1.02B | 1.00B | 1.29B | 1.50B | 1.23B | 1.27B | 1.11B | 787M | 595M | 1.30B | 377M |
| Total Liabilities | 709M | 675M | 811M | 795M | 674M | 924M | 915M | 728M | 721M | 812M | 200M |
| Shareholders' Equity | 310M | 329M | 476M | 706M | 559M | 350M | 194M | 58.9M | -126M | 491M | 177M |
| Cash & Short-term Investments | 282M | 328M | 590M | 817M | 505M | 504M | 132M | 171M | 123M | 912M | 153M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 156M | 147M | 242M | 287M | 16.8M | -229M | -157M | -141M | -327M | -195M | -326M |
| Capital Expenditure | 1.40M | 1.10M | 2.90M | 5.00M | 29.4M | 24.7M | 23.9M | 30.5M | 4.70M | 0.00 | 6.53M |
| Free Cash Flow | - | 145M | 238M | 255M | -173M | -282M | -181M | -172M | -331M | -195M | -333M |
| Ratios | |||||||||||
| ROE | 9.3% | 7.0% | 29.0% | 31.0% | -15.1% | -63.9% | -91.6% | -217.8% | - | 130.3% | -248.6% |
| ROA | 2.8% | 2.3% | 10.7% | 14.6% | -6.8% | -17.5% | -16.0% | -16.3% | -34.1% | 49.1% | -117.0% |
| Net Profit Margin | 4.1% | 3.6% | 17.6% | 25.9% | -12.7% | -39.6% | -28.4% | -20.1% | -683.5% | 2,458.8% | -3,555.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Orexo AB (publ) dividends
Orexo AB (publ) has not paid dividends in the last 9 fiscal years.
Who owns Orexo AB (publ)
- Insiders 10.13%
- Institutions 47.93%
- Public & others 41.94%
- Shares outstanding 56.1M
- Free float 22.5M
Orexo AB (publ) company profile
- Company name
- Orexo AB (publ)
- Ticker
- C5G.F
- ISIN
- SE0000736415
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 55
- Fiscal year end
- December
- Address
- Virdings allé 22, Uppsala, Sweden
- Phone
- 46 1 87 80 88 00
- Website
- orexo.com
About Orexo AB (publ)
Orexo AB (publ), a pharmaceutical company, provides advance treatments for severe diseases and life-saving rescue medications in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; Edluar for the treatment of insomnia; and Diabact UBT for the treatment of diagnosis of Helicobacter pylori. The company is developing Izipry for opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; OX390 for overdoses caused by a combination of life-threatening illicit drugs; OX125 for opioid overdose with powder-based nalmefene; OX472 for intranasal formulation of semaglutide, a GLP-1 receptor agonist, developed using proprietary AmorphOX technology; and develops thermostable and needle-free mucosal vaccines. Orexo AB (publ) was incorporated in 1994 and is headquartered in Uppsala, Sweden.
Orexo AB (publ) management
8- Mr. Nikolaj SorensenPresident & CEO · born 1972
- Mr. Fredrik JarrstenExecutive VP & CFO · born 1967
- Ms. Cecilia CouplandSenior VP & Head of Operations · born 1976
- Lena WangeInvestor Relations & Communications Director
- Mr. Robert RonnSenior VP and Head of R&D · born 1976
- Dr. Edward Kim M.B.A., M.D.Senior VP & Chief Medical Officer
- Ms. Lisa MooreSenior Vice President of Products & Portfolio Strategy
- Ms. Raheleh NassajiSenior Vice President of Business Development